GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
NCT00242372
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
370
Enrollment
INDUSTRY
Sponsor class
Stopped
The development program has been terminated
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:
Tesaglitazar 0.5
DRUG:
Insulin at least 30 units/day
Sponsor
AstraZeneca